| 臺大學術典藏 |
2022-04-25T06:44:21Z |
Prediction of Breast Cancer Recurrence Using a Deep Convolutional Neural Network Without Region-of-Interest Labeling
|
Phan N.N;Hsu C.-Y;Huang C.-C;Tseng L.-M;Chuang E.Y.; Phan N.N; Hsu C.-Y; Huang C.-C; Tseng L.-M; Chuang E.Y.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2022-04-25T06:44:19Z |
Predicting Breast Cancer Gene Expression Signature by Applying Deep Convolutional Neural Networks From Unannotated Pathological Images
|
Phan N.N;Huang C.-C;Tseng L.-M;Chuang E.Y.; Phan N.N; Huang C.-C; Tseng L.-M; Chuang E.Y.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-03-10T02:31:36Z |
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
|
Liu C.-Y.; Lau K.-Y.; Hsu C.-C.; Chen J.-L.; Lee C.-H.; Huang T.-T.; Chen Y.-T.; Huang C.-T.; PO-HAN LIN; Tseng L.-M. |
| 臺大學術典藏 |
2022-03-10T02:31:35Z |
Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells
|
Liu C.-Y.; Chu P.-Y.; Huang C.-T.; Chen J.-L.; Yang H.-P.; Wang W.-L.; Lau K.-Y.; Lee C.-H.; Lan T.-Y.; Huang T.-T.; PO-HAN LIN; Dai M.-S.; Tseng L.-M. |
| 臺大學術典藏 |
2022-03-10T02:31:33Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 國立成功大學 |
2022 |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin, P.-H.;Chen, S.-C.;Tseng, L.-M.;Chang, K.-J.;Huang, A.-C.;Cheng, K.-C.;Yang, K.;Wu, H.-C.;Chao, T.-Y.;Chang, Y.-C.;Lin, P.-C.;Kuo, W.-H.;Kuo, W.-L.;Lin, C.-H.;Chen, H.-M.;Yeh, D.-C.;Liu, Liu L.-C.;Liu, C.-Y.;Wang, M.-Y.;Lo, C.;Lu, Y.-S.;Huang, C.-S. |
| 國立成功大學 |
2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
|
Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
